secwatch.observer — SEC 8-K summary
======================================

Issuer:     BECTON DICKINSON & CO (BDX)
CIK:        0000010795
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0000010795-24-000064
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BD Q3 adjusted EPS $3.50 beats, raises FY24 guidance; acquires Edwards Critical Care for $4.2B
--------------------------------------------------------------------------------

- Revenue $4.99B as reported, $5.057B adjusted; organic revenue growth 5.2% YoY.
- GAAP diluted EPS $1.68 (+23.5% YoY); adjusted diluted EPS $3.50 (+18.2% YoY).
- Year-to-date free cash flow $2.2B, up over 100% YoY.
- FY2024 adjusted EPS guidance raised to $13.05-$13.15; organic revenue growth guidance 5.0%-5.25%.
- Announced agreement to acquire Edwards Lifesciences' Critical Care Product Group for $4.2B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10795/000001079524000064/0000010795-24-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10795/000001079524000064/bdx-20240801.htm
  HTML page:      https://secwatch.observer/filing/0000010795-24-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer